Janssen acquires Cerecor compound | August 21, 2017 Issue - Vol. 95 Issue 33 | Chemical & Engineering News
Volume 95 Issue 33 | p. 19 | Concentrates
Issue Date: August 21, 2017 | Web Date: August 20, 2017

Janssen acquires Cerecor compound

Department: Business
Keywords: neuroscience, Janssen, depression, nicotineb

Janssen Pharmaceuticals has acquired the selective kappa opioid receptor antagonist CERC-501 from Cerecor for $25 million plus a possible $20 million milestone payment. Baltimore-based Cerecor acquired CERC-501 from Eli Lilly & Co. in early 2015 and was developing the drug as a treatment for depression and substance use disorders. Late last year, Cerecor announced that CERC-501 failed in a trial as a treatment for nicotine withdrawal.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment